title: Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains.
abstract: Following achievement of polio eradication, the routine use of all live-attenuated oral poliovirus vaccines should be discontinued. However, the costs per vaccine dose for the alternative inactivated poliovirus vaccine (IPV) are significantly higher and the current production capacity is not sufficient for worldwide distribution of the vaccine. In order to achieve cost-prize reduction and improve affordability, IPV production processes and dose-sparing strategies should be developed to facilitate local manufacture at a relatively lower cost. The use of attenuated Sabin instead of wild-type polio strains will provide additional safety during vaccine production and permits production in low-cost settings. Sabin-IPV is under development by several manufacturers. This article gives an overview of results from clinical trials with Sabin-IPV and discusses the requirements and challenges in the clinical development of this novel IPV.
authors: Vaccinology Unit, RIVM, Antonie van Leeuwenhoeklaan 9, PO Box 1, 3720 BA Bilthoven, The Netherlands. pauline.verdijk@rivm.nl
authors: Pauline
authors: P
authors: Verdijk
authors: Nynke Y
authors: NY
authors: Rots
authors: Wilfried A M
authors: WA
authors: Bakker